Iodine-125 and PCV Combination Therapy

Based on the search results, I can provide information about the combination therapy of iodine-125, lomustine, procarbazine, and vincristine. This appears to be a combination treatment approach used primarily for brain tumors, particularly gliomas. The treatment combines external radiation therapy (using iodine-125) with a chemotherapy regimen known as PCV (procarbazine, lomustine/CCNU, and vincristine). ## Treatment Components The combination consists of: 1. **Iodine-125**: A radioisotope used in interstitial high-activity implants, typically administered after external radiation therapy. It delivers localized radiation doses of 5000-6000 cGy to the tumor site[1]. 2. **PCV Chemotherapy**: A combination of three chemotherapy drugs: - **Lomustine (CCNU)**: An oral alkylating agent, typically administered at doses of 75-130 mg/m² on day 1 of each cycle[4][9]. - **Procarbazine**: An oral chemotherapy drug, usually given at 60 mg/m² daily on days 8-21 of each cycle[4][9]. - **Vincristine**: Administered intravenously at 1.4 mg/m² (maximum 2 mg) on days 8 and 29 of each cycle[4][9]. ## Administration Method The treatment protocol typically involves: 1. External radiation therapy (approximately 6000 cGy)[1] 2. Followed by an interstitial implant of high-activity iodine-125 (5000-6000 cGy)[1] 3. Combined with multiple courses of PCV chemotherapy[1] The PCV component is administered as follows: - Lomustine is taken orally as capsules - Procarbazine is taken orally as capsules - Vincristine is administered intravenously through a central line, PICC line, portacath, or cannula[2][6] ## Clinical Evidence This combination approach has shown positive outcomes in clinical trials: - The addition of PCV chemotherapy to radiation therapy has been demonstrated to lengthen both disease control and survival compared to radiation therapy alone in patients with anaplastic oligodendroglial tumors[5]. - In a study with long-term follow-up (median 11.9 years), patients who received sequential radiation therapy followed by PCV chemotherapy had significantly longer median overall survival (13.3 years vs. 7.8 years) compared to radiation therapy alone[9]. - Five- and ten-year overall survival rates for radiation therapy plus PCV versus radiation therapy alone were 72% vs. 63% and 60% vs. 40%, respectively[9]. ## Side Effects and Toxicity The main side effects and toxicities associated with this combination include: - Hematological toxicity (particularly with lomustine) - Radiation necrosis - Potential for dose reductions due to toxicity[4] The treatment requires careful monitoring, with any toxicity grade 2 or greater potentially requiring dose reduction, delay, or omission of treatment[3]. This combination represents an important treatment option for certain types of brain tumors, particularly gliomas, though it's worth noting that in some contexts, temozolomide has been used as an alternative to PCV due to its lower toxicity profile[5][10].

Other names

I-125 + PCVIodine-125 + Lomustine + Procarbazine + VincristineSequential Radiation Therapy followed by PCV Chemotherapy